{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:56:15Z","timestamp":1765961775976,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>This case series reports clinical features and outcome of four patients with non-systemic vasculitic neuropathy (NSVN) treated with the anti-CD20 agent rituximab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Clinical, electrophysiological and biopsy data were retrospectively obtained and evaluated. Only patients with pathological definite or probable NSVN were included. Extensive clinical and laboratory work-up excluded systemic vasculitis. Follow-up data for at least 12\u00a0months and up to five years is provided. Outcome of the patients was assessed using the MRC-Sum Score, Prineas Score and Neurological Symptom Score.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Two of four patients treated with rituximab achieved disease remission and one patient remained stable under anti-CD20 therapy after a required treatment switch due to toxic side effects of cyclophosphamide. One patient deteriorated under rituximab induction. Rituximab was well tolerated in all patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Anti-CD20 therapy might be an alternative in NSVN patients requiring further treatment escalation or treatment switch due to side effects of corticosteroids or cyclophosphamide.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-024-12378-1","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T14:02:25Z","timestamp":1713967345000},"page":"4406-4411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rituximab in non-systemic vasculitic neuropathy: a single-center experience"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4429-0367","authenticated-orcid":false,"given":"Felix","family":"Kohle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilbert","family":"Wunderlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gereon R.","family":"Fink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Schroeter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmar C.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"12378_CR1","doi-asserted-by":"publisher","first-page":"175628642211371","DOI":"10.1177\/17562864221137129","volume":"16","author":"F Kohle","year":"2023","unstructured":"Kohle F, Dalakas MC, Lehmann HC (2023) Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy? Ther Adv Neurol Disord 16:17562864221137128","journal-title":"Ther Adv Neurol Disord"},{"key":"12378_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrneurol.2017.42","volume":"13","author":"MP Collins","year":"2017","unstructured":"Collins MP, Hadden RD (2017) The nonsystemic vasculitic neuropathies. Nat Rev Neurol 13:302\u2013316","journal-title":"Nat Rev Neurol"},{"key":"12378_CR3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1529-8027.2010.00281.x","volume":"15","author":"MP Collins","year":"2010","unstructured":"Collins MP, Dyck PJ, Gronseth GS, Guillevin L, Hadden RD, Heuss D, L\u00e9ger JM, Notermans NC, Pollard JD, Said G, Sobue G, Vrancken AF, Kissel JT (2010) Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst 15:176\u2013184","journal-title":"J Peripher Nerv Syst"},{"key":"12378_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s42466-022-00198-5","volume":"4","author":"C Schneider","year":"2022","unstructured":"Schneider C, Wassermann MK, Fink GR, Lehmann HC (2022) Single-center experience of induction therapy in non-systemic vasculitic neuropathy. Neurol Res Pract 4:32","journal-title":"Neurol Res Pract"},{"key":"12378_CR5","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1007\/s00415-015-7813-5","volume":"262","author":"N \u00dc\u00e7eyler","year":"2015","unstructured":"\u00dc\u00e7eyler N, Geng A, Reiners K, Toyka KV, Sommer C (2015) Non-systemic vasculitic neuropathy: single-center follow-up of 60 patients. J Neurol 262:2092\u20132100","journal-title":"J Neurol"},{"key":"12378_CR6","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/mus.880141111","volume":"14","author":"RP Kleyweg","year":"1991","unstructured":"Kleyweg RP, Van Der Mech\u00e9 FGA, Schmitz PIM (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barr\u00e9 syndrome. Muscle Nerve 14:1103\u20131109","journal-title":"Muscle Nerve"},{"key":"12378_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0404.1970.tb07459.x","volume":"44","author":"J Prineas","year":"1970","unstructured":"Prineas J (1970) Polyneuropathies of undetermined cause. Acta Neurol Scand Suppl 44:1\u201372","journal-title":"Acta Neurol Scand Suppl"},{"key":"12378_CR8","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/ana.410080608","volume":"8","author":"PJ Dyck","year":"1980","unstructured":"Dyck PJ, Sherman WR, Hallcher LM, Service FJ, O\u2019Brien PC, Grina LA, Palumbo PJ, Swanson CJ (1980) Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 8:590\u2013596","journal-title":"Ann Neurol"},{"key":"12378_CR9","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A, Khouatra C, Auma\u00eetre O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P, Qu\u00e9meneur T, Blanchard-Delaunay C, Godmer P, Pu\u00e9chal X, Carron PL, Hatron PY, Limal N, Hamidou M, Ducret M, Daugas E, Papo T, Bonnotte B, Mahr A, Ravaud P, Mouthon L (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371:1771\u20131780","journal-title":"N Engl J Med"},{"key":"12378_CR10","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1136\/jnnp-2017-315878","volume":"88","author":"C Schneider","year":"2017","unstructured":"Schneider C, Wunderlich G, Bleistein J, Fink GR, Deckert M, Brunn A, Lehmann HC (2017) Lymphocyte antigens targetable by monoclonal antibodies in non-systemic vasculitic neuropathy. J Neurol Neurosurg Psychiatry 88:756\u2013760","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12378_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00835","author":"K Hofmann","year":"2018","unstructured":"Hofmann K, Clauder A-K, Manz RA (2018) Targeting B cells and plasma cells in autoimmune diseases. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2018.00835","journal-title":"Front Immunol"},{"key":"12378_CR12","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1084\/jem.20051954","volume":"203","author":"DM Catron","year":"2006","unstructured":"Catron DM, Rusch LK, Hataye J, Itano AA, Jenkins MK (2006) CD4+ T cells that enter the draining lymph nodes after antigen injection participate in the primary response and become central-memory cells. J Exp Med 203:1045\u20131054","journal-title":"J Exp Med"},{"key":"12378_CR13","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41467-018-04418-y","volume":"9","author":"GD Garc\u00eda Nores","year":"2018","unstructured":"Garc\u00eda Nores GD, Ly CL, Cuzzone DA, Kataru RP, Hespe GE, Torrisi JS, Huang JJ, Gardenier JC, Savetsky IL, Nitti MD, Yu JZ, Rehal S, Mehrara BJ (2018) CD4+ T cells are activated in regional lymph nodes and migrate to skin to initiate lymphedema. Nat Commun 9:1970","journal-title":"Nat Commun"},{"key":"12378_CR14","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000407","volume":"4","author":"M Takahashi","year":"2017","unstructured":"Takahashi M, Koike H, Ikeda S, Kawagashira Y, Iijima M, Hashizume A, Katsuno M, Sobue G (2017) Distinct pathogenesis in nonsystemic vasculitic neuropathy and microscopic polyangiitis. Neurol Neuroimmunol Neuroinflamm 4:e407","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12378_CR15","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1007\/s00415-021-10744-x","volume":"269","author":"M Margoni","year":"2022","unstructured":"Margoni M, Preziosa P, Filippi M, Rocca MA (2022) Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol 269:1316\u20131334","journal-title":"J Neurol"},{"issue":"18","key":"12378_CR16","volume":"185","author":"AM Witt","year":"2023","unstructured":"Witt AM, Kodal LS, Pedersen BS, Lund EL, Dysgaard T (2023) Misinterpretation of non-systemic vasculitic neuropathy results in delayed treatment. Ugeskr Laeger 185(18):V10220665","journal-title":"Ugeskr Laeger"},{"key":"12378_CR17","doi-asserted-by":"publisher","first-page":"4884","DOI":"10.1093\/rheumatology\/keab069","volume":"60","author":"K Lima","year":"2021","unstructured":"Lima K, Tavee J, Dua A (2021) Combination rituximab and intravenous immunoglobulin for treatment of refractory vasculitic neuropathy: a case series. Rheumatology 60:4884\u20134887","journal-title":"Rheumatology"},{"key":"12378_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00415-020-10362-z","volume":"269","author":"CG Chisari","year":"2022","unstructured":"Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F (2022) Rituximab for the treatment of multiple sclerosis: a review. J Neurol 269:159\u2013183","journal-title":"J Neurol"},{"key":"12378_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00415-018-9092-4","volume":"266","author":"G Ellrichmann","year":"2019","unstructured":"Ellrichmann G, Bolz J, Peschke M, Duscha A, Hellwig K, Lee DH, Linker RA, Gold R, Haghikia A (2019) Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica\/neuromyelitis optica spectrum disorders. J Neurol 266:57\u201367","journal-title":"J Neurol"},{"key":"12378_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1365-2141.2008.07024.x","volume":"141","author":"P Kapoor","year":"2008","unstructured":"Kapoor P, Greipp PT, Morice WG, Rajkumar SV, Witzig TE, Greipp PR (2008) Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol 141:135\u2013148","journal-title":"Br J Haematol"},{"key":"12378_CR21","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000061","volume":"2","author":"JS Perumal","year":"2015","unstructured":"Perumal JS, Kister I, Howard J, Herbert J (2015) Disease exacerbation after rituximab induction in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2:e61","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12378_CR22","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.amjmed.2015.02.017","volume":"128","author":"P Cacoub","year":"2015","unstructured":"Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D (2015) Cryoglobulinemia Vasculitis. Am J Med 128:950\u2013955","journal-title":"Am J Med"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12378-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12378-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12378-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T10:34:59Z","timestamp":1720521299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12378-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["12378"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12378-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2024,4,24]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FK and CS report no disclosures relevant to the manuscript. GW has received advisory board honoraria and speaker fees from Alnylam, Biogen, Hormosan, Pfizer and Sobi outside of the submitted work. MS has received speaker honoraria from Alexion Pharmaceuticals, argenx, Bayer, Biogen, CSL Behring, Genzyme, Grifols, Merck, Miltenyi Biotec, Novartis, Roche, Teva, and Hormosan Pharma. He is vice chairman of the medical advisory board of the German Myasthenia Gravis Society. GRF received royalties from Springer, Thieme and Hogrefe. He declared speaker honoraria from Forum f\u00fcr medizinische Fortbildung (FomF) GmbH and the Deutsche Gesellschaft f\u00fcr Neurologie (DGN). HCL received honoraria for speaking and advisory board engagement or academic research support by Akcea, Alnylam, Biogen, Celgene, CSL Behring, Grifols, Gruenenthal, LFB Pharma, Takeda and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by the local ethic committee of the University of Cologne (21-1330).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}